Log in
NASDAQ:NEOS

Neos Therapeutics Stock Forecast, Price & News

$0.64
-0.01 (-1.54 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.63
Now: $0.64
$0.69
50-Day Range
$0.65
MA: $0.69
$0.79
52-Week Range
$0.60
Now: $0.64
$1.98
Volume130,100 shs
Average Volume209,184 shs
Market Capitalization$31.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Read More
Neos Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.95 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.65 million
Book Value($0.12) per share

Profitability

Net Income$-16,900,000.00

Miscellaneous

Employees215
Market Cap$31.75 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$0.64
-0.01 (-1.54 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

How has Neos Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NEOS shares have decreased by 53.8% and is now trading at $0.6382.
View which stocks have been most impacted by COVID-19
.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Neos Therapeutics
.

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics Inc (NASDAQ:NEOS) issued its earnings results on Monday, August, 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.02. The business earned $13.13 million during the quarter.
View Neos Therapeutics' earnings history
.

Who are some of Neos Therapeutics' key competitors?

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include SCYNEXIS (SCYX), Verastem (VSTM), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the following people:
  • Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 61)
  • Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)
  • Mr. John P. Limongelli, Sr. VP & Gen. Counsel (Age 49)
  • Mr. Darren Heath, VP of Sales
  • Mr. Russ McMahen, Sr. VP of R&D

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Who are Neos Therapeutics' major shareholders?

Neos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (5.32%), Jacobs Levy Equity Management Inc. (0.79%) and Bridgeway Capital Management Inc. (0.71%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt.
View institutional ownership trends for Neos Therapeutics
.

Which institutional investors are buying Neos Therapeutics stock?

NEOS stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Bridgeway Capital Management Inc., and Goldman Sachs Group Inc.. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin, and Richard I Eisenstadt.
View insider buying and selling activity for Neos Therapeutics
.

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $0.64.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $31.75 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.

What is Neos Therapeutics' official website?

The official website for Neos Therapeutics is www.neostx.com.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.